Novelion Therapeutics, Inc. engages in the development and commercialization of pharmaceuitical products. It focuses in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and is headquartered in Vancouver, Canada.
Company profile
Ticker
NVLN, NVLNF
Exchange
Website
CEO
Benjamin J. Harshbarger
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
QLT Inc, QLT Photo Therapeutics Inc, QLT Phototherapeutics Inc, Quadra Logic Tech. Inc.
SEC CIK
Corporate docs
NVLN stock data
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
10 Mar 23
8-K
Novelion Therapeutics Ceases to be a Reporting Issuer in Canada
14 Jul 20
8-K
Novelion Therapeutics Provides Update on Liquidation and Claims Process
12 Jun 20
NT 10-K
Notice of late annual filing
30 Mar 20
8-K
Bankruptcy or Receivership
21 Jan 20
8-K
Other Events
10 Jan 20
8-K
Novelion Therapeutics Provides Updates on Voluntary Liquidation and Other Matters
3 Jan 20
25-NSE
Exchange delisting
17 Dec 19
8-K
Novelion Therapeutics Provides Update on Effective Date of Liquidation
11 Dec 19
8-K
Other Events
22 Nov 19
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G/A
Novelion Therapeutics Inc.
21 Jan 20
3
KEVIN KOTLER
15 Jan 20
SC 13G/A
Novelion Therapeutics Inc.
15 Jan 20
SC 13G/A
Novelion Therapeutics Inc.
10 Jan 20
4
Change in insider ownership
12 Dec 19
4
Change in insider ownership
9 Dec 19
4
Change in insider ownership
26 Nov 19
4
Change in insider ownership
16 Oct 19
3
Initial statement of insider ownership
2 Oct 19
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|